# Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

> **NCT02739828** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 24 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **BIOLOGICAL:** Adalimumab

## Key facts

- **NCT ID:** NCT02739828
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-07
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739828, "Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02739828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*